193 related articles for article (PubMed ID: 33883647)
1. Development and evaluation of physiologically based pharmacokinetic drug-disease models for predicting captopril pharmacokinetics in chronic diseases.
Rasool MF; Ali S; Khalid S; Khalid R; Majeed A; Imran I; Saeed H; Usman M; Ali M; Alali AS; AlAsmari AF; Ali N; Asiri AM; Alasmari F; Alqahtani F
Sci Rep; 2021 Apr; 11(1):8589. PubMed ID: 33883647
[TBL] [Abstract][Full Text] [Related]
2. Application of a physiologically based pharmacokinetic model in predicting captopril disposition in children with chronic kidney disease.
Khalid S; Rasool MF; Masood I; Imran I; Saeed H; Ahmad T; Alqahtani NS; Alshammari FA; Alqahtani F
Sci Rep; 2023 Feb; 13(1):2697. PubMed ID: 36792681
[TBL] [Abstract][Full Text] [Related]
3. A physiologically based pharmacokinetic drug-disease model to predict carvedilol exposure in adult and paediatric heart failure patients by incorporating pathophysiological changes in hepatic and renal blood flows.
Rasool MF; Khalil F; Läer S
Clin Pharmacokinet; 2015 Sep; 54(9):943-62. PubMed ID: 25773479
[TBL] [Abstract][Full Text] [Related]
4. Development and Evaluation of Physiologically Based Pharmacokinetic Drug-Disease Models for Predicting Rifampicin Exposure in Tuberculosis and Cirrhosis Populations.
Rasool MF; Khalid S; Majeed A; Saeed H; Imran I; Mohany M; Al-Rejaie SS; Alqahtani F
Pharmaceutics; 2019 Nov; 11(11):. PubMed ID: 31694244
[TBL] [Abstract][Full Text] [Related]
5. Predicting Stereoselective Disposition of Carvedilol in Adult and Pediatric Chronic Heart Failure Patients by Incorporating Pathophysiological Changes in Organ Blood Flows-A Physiologically Based Pharmacokinetic Approach.
Rasool MF; Khalil F; Läer S
Drug Metab Dispos; 2016 Jul; 44(7):1103-15. PubMed ID: 27068272
[TBL] [Abstract][Full Text] [Related]
6. A Physiologically Based Pharmacokinetic Model for Predicting Diazepam Pharmacokinetics after Intravenous, Oral, Intranasal, and Rectal Applications.
Khalid S; Rasool MF; Imran I; Majeed A; Saeed H; Rehman AU; Ashraf W; Ahmad T; Bin Jardan YA; Alqahtani F
Pharmaceutics; 2021 Sep; 13(9):. PubMed ID: 34575556
[TBL] [Abstract][Full Text] [Related]
7. A physiologically based pharmacokinetic model of cefepime to predict its pharmacokinetics in healthy, pediatric and disease populations.
Talha Zahid M; Zamir A; Majeed A; Imran I; Alsanea S; Ahmad T; Alqahtani F; Fawad Rasool M
Saudi Pharm J; 2023 Aug; 31(8):101675. PubMed ID: 37576858
[TBL] [Abstract][Full Text] [Related]
8. Assessment of the Utility of Physiologically-based Pharmacokinetic Model for prediction of Pharmacokinetics in Chinese and Japanese Populations.
Yu Y; Lin J; Muto C; Li Y; Mori Y; Mittapalli RK; Tse S; Liu J; Ge BK; Liu J
Int J Med Sci; 2021; 18(16):3718-3727. PubMed ID: 34790045
[TBL] [Abstract][Full Text] [Related]
9. Physiologically based pharmacokinetic modelling to predict exposure differences in healthy volunteers and subjects with renal impairment: Ceftazidime case study.
Zhou L; Tong X; Sharma P; Xu H; Al-Huniti N; Zhou D
Basic Clin Pharmacol Toxicol; 2019 Aug; 125(2):100-107. PubMed ID: 30739396
[TBL] [Abstract][Full Text] [Related]
10. Investigating the Role of Altered Systemic Albumin Concentration on the Disposition of Theophylline in Adult and Pediatric Patients with Asthma by Using the Physiologically Based Pharmacokinetic Approach.
Rasool MF; Khalid R; Imran I; Majeed A; Saeed H; Alasmari F; Alanazi MM; Alqahtani F
Drug Metab Dispos; 2020 Jul; 48(7):570-579. PubMed ID: 32393652
[TBL] [Abstract][Full Text] [Related]
11. Optimizing the Clinical Use of Carvedilol in Liver Cirrhosis Using a Physiologically Based Pharmacokinetic Modeling Approach.
Rasool MF; Khalil F; Läer S
Eur J Drug Metab Pharmacokinet; 2017 Jun; 42(3):383-396. PubMed ID: 27313074
[TBL] [Abstract][Full Text] [Related]
12. Predicting Hydroxychloroquine Clearance in Healthy and Diseased Populations Using a Physiologically Based Pharmacokinetic Approach.
Alqahtani F; Asiri AM; Zamir A; Rasool MF; Alali AS; Alsanea S; Walbi IA
Pharmaceutics; 2023 Apr; 15(4):. PubMed ID: 37111735
[TBL] [Abstract][Full Text] [Related]
13. Development and evaluation of a physiologically based pharmacokinetic model to predict carvedilol-paroxetine metabolic drug-drug interaction in healthy adults and its extrapolation to virtual chronic heart failure patients for dose optimization.
Rasool MF; Läer S
Expert Opin Drug Metab Toxicol; 2021 Jun; 17(6):717-724. PubMed ID: 33910429
[No Abstract] [Full Text] [Related]
14. Physiologically Based Pharmacokinetic Model To Predict Metoprolol Disposition in Healthy and Disease Populations.
Zamir A; Rasool MF; Imran I; Saeed H; Khalid S; Majeed A; Rehman AU; Ahmad T; Alasmari F; Alqahtani F
ACS Omega; 2023 Aug; 8(32):29302-29313. PubMed ID: 37599939
[TBL] [Abstract][Full Text] [Related]
15. Physiologically Based Pharmacokinetic Modelling and Prediction of Metformin Pharmacokinetics in Renal/Hepatic-Impaired Young Adults and Elderly Populations.
Rhee SJ; Chung H; Yi S; Yu KS; Chung JY
Eur J Drug Metab Pharmacokinet; 2017 Dec; 42(6):973-980. PubMed ID: 28536774
[TBL] [Abstract][Full Text] [Related]
16. PBPK Modeling of the Effect of Reduced Kidney Function on the Pharmacokinetics of Drugs Excreted Renally by Organic Anion Transporters.
Hsueh CH; Hsu V; Zhao P; Zhang L; Giacomini KM; Huang SM
Clin Pharmacol Ther; 2018 Mar; 103(3):485-492. PubMed ID: 28738449
[TBL] [Abstract][Full Text] [Related]
17. Development of 4-Pyridoxic Acid PBPK Model to Support Biomarker-Informed Evaluation of OAT1/3 Inhibition and Effect of Chronic Kidney Disease.
Tan SPF; Willemin ME; Snoeys J; Shen H; Rostami-Hodjegan A; Scotcher D; Galetin A
Clin Pharmacol Ther; 2023 Dec; 114(6):1243-1253. PubMed ID: 37620246
[TBL] [Abstract][Full Text] [Related]
18. Development and Evaluation of a Physiologically Based Pharmacokinetic Drug-Disease Model of Propranolol for Suggesting Model Informed Dosing in Liver Cirrhosis Patients.
Kalam MN; Rasool MF; Alqahtani F; Imran I; Rehman AU; Ahmed N
Drug Des Devel Ther; 2021; 15():1195-1211. PubMed ID: 33762817
[TBL] [Abstract][Full Text] [Related]
19. Human pharmacokinetic profiling of the dipeptidyl peptidase-IV inhibitor teneligliptin using physiologically based pharmacokinetic modeling.
Nakamaru Y; Emoto C; Shimizu M; Yamazaki H
Biopharm Drug Dispos; 2015 Apr; 36(3):148-62. PubMed ID: 25450725
[TBL] [Abstract][Full Text] [Related]
20. Physiologically based pharmacokinetic models in the prediction of oral drug exposure over the entire pediatric age range-sotalol as a model drug.
Khalil F; Läer S
AAPS J; 2014 Mar; 16(2):226-39. PubMed ID: 24399240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
